Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position: Cash and cash equivalents were $3.7 ...
Cash Position: Cash and cash equivalents were $4.4 million as of September 30, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Exicure, Inc. (XCUR) today shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor. In addition to AML, GPC-100 is currently ...
Exicure, Inc. (Nasdaq: XCUR, “the Company”, “Exicure”), today announced that in connection with the change of control transaction approved by the stockholders at the Special Meeting of the ...
Exicure, Inc. (Nasdaq: XCUR, the "Company") announced today that its Special Meeting of Stockholders (the "Special Meeting") scheduled for and convened on August 15, 2024 has been adjourned for the ...
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Exicure, Inc. (NASDAQ: XCUR) between March 11, 2021 and November 15, 2021, inclusive (the "Class Period" ...
We recently compiled a list of the 10 Micro-, Small-Cap Companies Lead Monday’s Charge. In this article, we are going to take a look at where Exicure Inc. (NASDAQ:XCUR) stands against the other stocks ...
A look at the shareholders of Exicure, Inc. (NASDAQ:XCUR) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a ...
CHICAGO--(BUSINESS WIRE)-- Exicure, Inc. (XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results